A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout
Kihyoun Park, Injae Shin, Yoonseon Kim, Hyereen Kang, Soo-Jin Oh, Eunkyeong Jang, Taebo Sim, Jeehee Youn, Myung-Shik Lee · 2024
Read A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout by Kihyoun Park, Injae Shin, Yoonseon Kim, Hyereen Kang, Soo-Jin Oh, Eunkyeong Jang, Taebo Sim, Jeehee Youn, Myung-Shik Lee (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10869544.txt.
Description
Kihyoun Park and nine colleagues published a study of a new drug candidate against gout. Gout is caused by monosodium urate crystals that trigger the NLRP3 inflammasome, an immune complex that drives painful inflammation. A protein called NEK7 is essential for switching that complex on, making it a drug target.
The team designed NEK7 inhibitors from a family of thienopyrimidine compounds, screening them by kinome profiling. In macrophages from mouse bone marrow, the compounds were tested for their ability to block the release of interleukin-1 beta, the inflammasome's main output, after crystal stimulation. They also checked the binding between NLRP3 and NEK7 directly. A selective NEK7 blocker could calm gout flares at their source.
Catalog record
| CREATOR | Kihyoun Park, Injae Shin, Yoonseon Kim, Hyereen Kang, Soo-Jin Oh, Eunkyeong Jang, Taebo Sim, Jeehee Youn, Myung-Shik Lee |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |